# BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 YTD Q2 P&L / Income Statement - Company: BOSTON SCIENTIFIC CORPORATION (BSX) - Period: 2026-01-01 to 2026-06-30 - Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0000885725-26-000053 - Page: https://plicit.ai/financials/bsx/fy2026-ytd-q2-income-statement - Chart image: https://plicit.ai/charts/bsx-fy2026-ytd-q2-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 10,646,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 3,184,000,000 US dollars - **Gross profit**: 7,462,000,000 US dollars - **Operating expenses**: 5,183,000,000 US dollars - **Operating income (loss)**: 2,279,000,000 US dollars - **Other income (expense), net (calculated)**: negative 57,000,000 US dollars - **Income (loss) before income taxes**: 2,222,000,000 US dollars - **Income tax expense (benefit)**: negative 21,000,000 US dollars - **Net income (loss)**: 2,243,000,000 US dollars - **Cardiac Rhythm Management - UNITED STATES**: 698,000,000 US dollars - **Cardiac Rhythm Management - Int'l**: 465,000,000 US dollars - **Electrophysiology - UNITED STATES**: 1,209,000,000 US dollars - **Electrophysiology - Int'l**: 612,000,000 US dollars - **Endoscopy - UNITED STATES**: 937,000,000 US dollars - **Endoscopy - Int'l**: 593,000,000 US dollars - **Neuromodulation - UNITED STATES**: 494,000,000 US dollars - **Neuromodulation - Int'l**: 166,000,000 US dollars - **Urology - UNITED STATES**: 967,000,000 US dollars - **Urology - Int'l**: 363,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - UNITED STATES**: 1,139,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - Int'l**: 1,438,000,000 US dollars - **Interventional Oncology & Embolization - UNITED STATES**: 344,000,000 US dollars - **Interventional Oncology & Embolization - Int'l**: 207,000,000 US dollars - **Watchman - UNITED STATES**: 921,000,000 US dollars - **Watchman - Int'l**: 93,000,000 US dollars - **Selling, general and administrative expenses**: 3,583,000,000 US dollars - **Research and development expenses**: 1,069,000,000 US dollars - **Royalty expense**: 24,000,000 US dollars - **Amortization expense**: 466,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 46,000,000 US dollars - **Restructuring net charges (credits)**: 11,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $2.25 B; to noncontrolling interests: −$4.00 M. ## Chart details: Revenue by Business Segment - Page: https://plicit.ai/financials/bsx/fy2026-ytd-q2-income-statement/revenue-by-business-segment - Chart image: https://plicit.ai/charts/bsx-fy2026-ytd-q2-revenue-by-business-segment-sankey.png Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 10,646,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 3,184,000,000 US dollars - **Gross profit**: 7,462,000,000 US dollars - **Operating expenses**: 5,183,000,000 US dollars - **Operating income (loss)**: 2,279,000,000 US dollars - **Other income (expense), net (calculated)**: negative 57,000,000 US dollars - **Income (loss) before income taxes**: 2,222,000,000 US dollars - **Income tax expense (benefit)**: negative 21,000,000 US dollars - **Net income (loss)**: 2,243,000,000 US dollars - **MedSurg**: 3,519,000,000 US dollars - **Cardiovascular**: 7,126,000,000 US dollars - **Undisclosed (calculated)**: 1,000,000 US dollars - **Selling, general and administrative expenses**: 3,583,000,000 US dollars - **Research and development expenses**: 1,069,000,000 US dollars - **Royalty expense**: 24,000,000 US dollars - **Amortization expense**: 466,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 46,000,000 US dollars - **Restructuring net charges (credits)**: 11,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $2.25 B; to noncontrolling interests: −$4.00 M. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/bsx/fy2026-ytd-q2-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/bsx-fy2026-ytd-q2-revenue-by-geography-sankey.png Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 10,646,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 3,184,000,000 US dollars - **Gross profit**: 7,462,000,000 US dollars - **Operating expenses**: 5,183,000,000 US dollars - **Operating income (loss)**: 2,279,000,000 US dollars - **Other income (expense), net (calculated)**: negative 57,000,000 US dollars - **Income (loss) before income taxes**: 2,222,000,000 US dollars - **Income tax expense (benefit)**: negative 21,000,000 US dollars - **Net income (loss)**: 2,243,000,000 US dollars - **UNITED STATES**: 6,709,000,000 US dollars - **Int'l**: 3,936,000,000 US dollars - **Undisclosed (calculated)**: 1,000,000 US dollars - **Selling, general and administrative expenses**: 3,583,000,000 US dollars - **Research and development expenses**: 1,069,000,000 US dollars - **Royalty expense**: 24,000,000 US dollars - **Amortization expense**: 466,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 46,000,000 US dollars - **Restructuring net charges (credits)**: 11,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $2.25 B; to noncontrolling interests: −$4.00 M. ## Chart details: Revenue by Product and Service - Page: https://plicit.ai/financials/bsx/fy2026-ytd-q2-income-statement/revenue-by-product-and-service - Chart image: https://plicit.ai/charts/bsx-fy2026-ytd-q2-revenue-by-product-and-service-sankey.png Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 10,646,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 3,184,000,000 US dollars - **Gross profit**: 7,462,000,000 US dollars - **Operating expenses**: 5,183,000,000 US dollars - **Operating income (loss)**: 2,279,000,000 US dollars - **Other income (expense), net (calculated)**: negative 57,000,000 US dollars - **Income (loss) before income taxes**: 2,222,000,000 US dollars - **Income tax expense (benefit)**: negative 21,000,000 US dollars - **Net income (loss)**: 2,243,000,000 US dollars - **Endoscopy**: 1,529,000,000 US dollars - **Urology**: 1,330,000,000 US dollars - **Neuromodulation**: 659,000,000 US dollars - **Interventional Cardiology & Vascular Therapies**: 2,577,000,000 US dollars - **Watchman**: 1,014,000,000 US dollars - **Electrophysiology**: 1,821,000,000 US dollars - **Cardiac Rhythm Management**: 1,163,000,000 US dollars - **Interventional Oncology & Embolization**: 551,000,000 US dollars - **Undisclosed (calculated)**: 2,000,000 US dollars - **Selling, general and administrative expenses**: 3,583,000,000 US dollars - **Research and development expenses**: 1,069,000,000 US dollars - **Royalty expense**: 24,000,000 US dollars - **Amortization expense**: 466,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 46,000,000 US dollars - **Restructuring net charges (credits)**: 11,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $2.25 B; to noncontrolling interests: −$4.00 M.